Press release
October 2nd 2024
APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s
Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease.
“With the introduction of new disease-modifying drugs for treating Alzheimer’s, a new era of therapy has begun for this incurable disease. However, it has been found that patients with a certain form of the APOE gene have a significant risk for developing potentially life-threating side effects, called ARIA, referring to edema or microbleedings in the brain,” explains Dr. Lars Komorowski, chief scientific officer of EUROIMMUN. “Being able to easily determine the APOE genotype of patients before starting therapy is key to assessing the individual risk for potential negative consequences.”
The real-time EURORealTime APOE PCR test allows simultaneous detection of the three most frequent APOE genotypes, designated E2, E3 and E4. Carriers of exclusively E4 exhibit the highest risk for ARIA under therapy. With the new test now available from Revvity’s EUROIMMUN, only one reaction is required using genomic DNA isolated from a single blood sample to determine the patient’s APOE genotype. The assay processing can be automated to scalable degrees on Revvity instruments, including the EUROIMMUN PreNAT IITM and the chemagic™ 360 platforms. Results are evaluated, documented and archived using the EURORealTime analysis software.
For clinicians treating Alzheimer’s patients, this approach to APOE genotyping will grant additional patient information and will enable a more personalized approach in anti-amyloid (beta) treatment.
Please find the official press release here.
Or do you want to learn more on the assay? Find further information on our website.